Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Fiscal Year: January - December
Eli Lilly and Company (LLY), listed on the NYSE, has a market capitalization of $. As of Jan 06, 2026, the stock is trading at $1,041.51 per share, offering investors a clear view of its current market value. Eli Lilly and Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 50.95, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Eli Lilly and Company also offers a dividend yield of 0.66%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Eli Lilly and Company (LLY) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Eli Lilly and Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Eli Lilly and Company, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Eli Lilly and Company is 100.58, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Eli Lilly and Company (LLY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Eli Lilly and Company (LLY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Eli Lilly and Company (LLY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Eli Lilly and Company. To access the full SS Score, consider upgrading your subscription.
Eli Lilly and Company is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 50.95. Investors should compare these metrics with industry peers to gauge whether Eli Lilly and Company is outperforming or underperforming within its sector.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
My Top 15 High-Growth Dividend Stock list delivered a 0.83% gain in December, outperforming SPY and VIG. The Value-tilted portfolio variant led with a 2.17% December return, suggesting undervaluation ...
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in Jan...
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE: LLY) and Novo Nord...
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis,...
Novo said it expects to launch the weight-loss pill in the U.S. in early January.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Weight loss drug Mounjaro's manufacturer, Eli Lilly and Co. (NYSE: LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This im...
From Micron (MU) leading a strong comeback in tech, to Eli Lilly's (LLY) developments on an oral GLP-1 drug, Marley Kayden and Sam Vadas turn to headlines that caught their attention in Thursday's reb...
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company's injection Zepbound and Nov...
CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from ...
Eli Lilly has a new pill, called orforglipron, it plans to launch next year.
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medicatio...
Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial...
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switch...
Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday, citing a note to pharmacies iss...
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 10.62B | 182.41% | Est @182.4% |
| 2026 | 17.48B | 64.59% | Analyst x5 |
| 2027 | 25.48B | 45.78% | Analyst x6 |
| 2028 | 30.97B | 21.54% | Analyst x5 |
| 2029 | 37.59B | 21.39% | Analyst x5 |
| 2030 | 42.86B | 14.01% | Analyst x5 |
| 2031 | 45.88B | 7.06% | Est @7.1% |
| 2032 | 48.48B | 5.68% | Est @5.7% |
| 2033 | 50.77B | 4.71% | Est @4.7% |
| 2034 | 52.68B | 3.76% | Est @3.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 792.50M | 1.00 | 792.50M |
| 2024A | 3.76B | 1.00 | 3.76B |
| 2025E | 10.62B | 1.08 | 9.86B |
| 2026E | 17.48B | 1.16 | 15.08B |
| 2027E | 25.48B | 1.25 | 20.42B |
| 2028E | 30.97B | 1.34 | 23.05B |
| 2029E | 37.59B | 1.45 | 25.98B |
| 2030E | 42.86B | 1.56 | 27.51B |
| 2031E | 45.88B | 1.68 | 27.36B |
| 2032E | 48.48B | 1.81 | 26.85B |
| 2033E | 50.77B | 1.94 | 26.12B |
| 2034E | 52.68B | 2.09 | 25.17B |
| Terminal | 1.05T | 2.09 | 499.48B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.